Sign in

NCT05918263Recruiting

Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: The REMOVE Trial

Source: ClinicalTrials.gov · Last updated 15 Jul 2026

Brief summary (registry, in English)

The purpose of this study is to determine whether a 12-week, home-based, virtually supervised exercise program will slow cancer progression of prostate cancer among men with prostate cancer at high-risk of progression undergoing active surveillance. The name of the study intervention involved in this study is: Aerobic high-intensity interval training (HIIT) (training exercise intervention)

Status (registry)
Recruiting
Study type
Interventional
Enrollment
68 (estimated)
First submitted
14 Jun 2023
Start date
1 Jan 2024
Primary completion date
31 Mar 2027
Lead sponsor
Fred Hutchinson Cancer Center
NCT number
NCT05918263

What you commit to

  • Study type: Interventional
  • Planned participants: 68
  • From 1 Jan 2024 to the primary completion date, 31 Mar 2027
  • 4 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Received any invasive curative-intent treatment for prostate cancer, including surgery, chemotherapy, radiation therapy, and hormonal therapy.
  • Patients with metastasis and/or other active malignancies (except basal cell carcinoma) and/or receiving treatment for those malignancies.

Other illness

  • Having chronic medical conditions that are clinically unstable or uncontrolled with medications, deemed high-risk for exercise. These include but are not limited to unstable cardiac diseases, uncontrolled diabetes, and bone metastases with imminent risk of fracture.
  • Having a high risk for noncompliance with study procedures. This will be determined by the study team based on the history of missed oncology appointments (i.e., ≥3 no-shows in 6 months) and poor responsiveness during recruitment (i.e., ≥3 unreturned contacts).

Other

  • Participating in any (\>0 min/week) high-intensity exercise at the time of recruitment.
  • Patients who are non-English speaking and unable to complete the participant surveys.

Who the study is looking for

  • Age ≥18 years.
  • Histologically diagnosed with localized prostate cancer.
  • Initiating or undergoing active surveillance.
  • Having a higher risk of progression, defined as meeting one or more of the following: (1) favorable- intermediate risk prostate tumor at diagnosis, (2) obesity (body mass index ≥ 30), and/or (3) self- identified as Black or African American.
  • No plans for invasive treatment for their prostate cancer in the 12 weeks following the time of enrollment.
  • Ability to understand and willingness to provide informed consent.

Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (4)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Dana-Farber Cancer Institute
Coordinator of this site? Confirm its status
BostonUnited StatesCompleted
Beth Israel Deaconess Medical Center
Coordinator of this site? Confirm its status
BostonUnited StatesCompleted
Brigham and Women's Hospital
Coordinator of this site? Confirm its status
BostonUnited StatesCompleted
Fred Hutch/University of Washington Cancer Consortium
Coordinator of this site? Confirm its status
SeattleUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.